CLAIMS

1. Use of a composition in the manufacture of a medicament for the treatment or prophylaxis of diseases in humans and animals, wherein the composition is obtained by removing the microorganisms from a growth medium in which intestinal microbiota and/or faeces have been anaerobically cultivated in a physiologically acceptable medium and freeing the medium from the microorganisms,

wherein the cultivated bacteria belong to at least three of the following four phyla: Bacterioidetes, Firmicutes, Proteobacteria and Actinobacteria, said microorganisms are identified as:

Bacteria;"Actinobacteria";Actinobacteria;Coriobacteridae;Coriobacteriales;"Coriobacterineae";Coriobacteriaceae;Collinsella,

Bacteria;"Actinobacteria";Actinobacteria;Coriobacteridae;Coriobacteriales;"Coriobacterineae";Coriobacteriaceae;Eggerthella,

Bacteria;"Actinobacteria";Actinobacteria;Coriobacteridae;Coriobacteriales;"Coriobacterineae";Coriobacteriaceae;Olsenella,

Bacteria;"Bacteroidetes";"Bacteroidia";"Bacteroidales";"Porphyromonadaceae";Parabacteroides,

Bacteria;"Bacteroidetes";"Bacteroidia";"Bacteroidales";"Prevotellaceae";Prevotella,

Bacteria;"Bacteroidetes";"Bacteroidia";"Bacteroidales";"Rikenellaceae";Alistipes,

Bacteria;"Bacteroidetes";"Bacteroidia";"Bacteroidales";Bacteroidaceae;Bacteroides

Bacteria;"Firmicutes";"Bacilli";"Lactobacillales";"Enterococcaceae";Enterococcus,

Bacteria;"Firmicutes";"Clostridia";Clostridiales;"Eubacteriaceae";Eubacterium

Bacteria;"Firmicutes";"Clostridia";Clostridiales;"Eubacteriaceae";unclassified_"Eubacteriaceae",

Bacteria;"Firmicutes";"Clostridia";Clostridiales;"Lachnospiraceae";Anaerostipes,

Bacteria;"Firmicutes";"Clostridia";Clostridiales;"Lachnospiraceae";Dorea,

Bacteria;"Firmicutes";"Clostridia";Clostridiales;"Lachnospiraceae";Roseburia,

Bacteria;"Firmicutes";"Clostridia";Clostridiales;"Lachnospiraceae";unclassified_"Lachnospiraceae",

Bacteria;"Firmicutes";"Clostridia";Clostridiales;"Peptostreptococcaceae";Sporacetigenium,

Bacteria;"Firmicutes";"Clostridia";Clostridiales;"Peptostreptococcaceae";unclassifie

d_"Peptostreptococcaceae",
Bacteria;"Firmicutes";"Clostridia";Clostridiales;"Ruminococcaceae";Anaerofilum,
Bacteria;"Firmicutes";"Clostridia";Clostridiales;"Ruminococcaceae";Anaerotruncus,
Bacteria;"Firmicutes";"Clostridia";Clostridiales;"Ruminococcaceae";Oscillibacter,
Bacteria;"Firmicutes";"Clostridia";Clostridiales;"Ruminococcaceae";unclassified_"Ruminococcaceae",
Bacteria;"Firmicutes";"Clostridia";Clostridiales;Clostridiaceae;"Clostridiaceae1";Clostridium,
Bacteria;"Firmicutes";"Clostridia";Clostridiales;Clostridiaceae;"Clostridiaceae1";Sarcina,
Bacteria;"Firmicutes";"Clostridia";Clostridiales;Clostridiaceae;"Clostridiaceae1";unclassified_"Clostridiaceae1",
Bacteria;"Firmicutes";"Clostridia";Clostridiales;IncertaeSedisXI;Anaerococcus,
Bacteria;"Firmicutes";"Clostridia";Clostridiales;IncertaeSedisXI;Finegoldia,
Bacteria;"Firmicutes";"Clostridia";Clostridiales;IncertaeSedisXI;Peptoniphilus,
Bacteria;"Firmicutes";"Clostridia";Clostridiales;IncertaeSedisXI;unclassified_IncertaeSedisXI,
Bacteria;"Firmicutes";"Clostridia";Clostridiales;IncertaeSedisXIII;Anaerovorax,
Bacteria;"Firmicutes";"Clostridia";Clostridiales;IncertaeSedisXIII;Mogibacterium,
Bacteria;"Firmicutes";"Clostridia";Clostridiales;IncertaeSedisXIV;Blautia,
Bacteria;"Firmicutes";"Clostridia";Clostridiales;unclassified_Clostridiales,
Bacteria;"Firmicutes";"Clostridia";Clostridiales;Veillonellaceae;Veillonella,
Bacteria;"Firmicutes";"Erysipelotrichi";"Erysipelotrichales";Erysipelotrichaceae;Holdemania, and
Bacteria;"Proteobacteria";Betaproteobacteria;Burkholderiales;Alcaligenaceae;Parasutterella;

wherein said growth medium is:
a physiologically acceptable medium, e.g. a physiological saline;

wherein
the microbiota is cultivated on bacterial growth media, preferably anaerobically, but also in the presence of sufficient oxygen and other metabolic electron acceptors to allow growth of facultative anaerobic and microaerophilic microorganisms.

2. The use according to claim 1, wherein the intestinal microbiota and/or the faeces were selected from humans.

3. The use according to claim 1, wherein the intestinal microbiota and/or the faeces were selected from animals.

4. The use according to any of claims 1-3, comprising a filtrate or a supernatant of a physiologically acceptable medium having been in contact with faeces.

5. The use according to claims 1-4, characterised in that the composition further contains substances and components which facilitates the administration or supports the effect of the invention, said substances and components are selected from β-glucans and/or thylakoids, bacterial, and algae preparations.

6. The use according to any one of claims 1-5, wherein the composition is a pharmaceutical composition.

7. The use according to claim 6, wherein the composition is used for the treatment or prophylaxis of diseases in humans and animals.

8. The use according claims 6-7, wherein the composition is used for the treatment of gastrointestinal pain.

9. The use according any one of claims 6-7, wherein the composition is used for the treatment of IBS and Chronic Fatigue Syndrome/Myalgic Encephalomyelitis.

10. The use according to any one of claims 6-7, wherein the composition is used for the treatment of diseases located in the gastrointestinal system, namely Irritable Bowel Syndrome (IBS), Celiac Disease and Inflammatory Bowel Diseases, e.g. Ulcerative Colitis, Crohn's Disease, Microscopic Colitis and Pauchitis, and also iatrogenic disturbance/dysbiosis in connection with radiotherapy, Chemotherapy,

transplantations or antibiotic related diarrhoea, especially related to Clostridium difficile (Clostridium difficile associated diarrhoea and recurrent Clostridium difficile infections).

11. The use according to any one of claims 6-7, wherein the composition is used for the treatment of rheumatologic disorders, e.g. rheumatoid arthritis.

12. The use according to any one of claims 6-7, wherein the composition is used for the treatment of disorders and diseases caused by dysbiosis in children from birth to the time when an adult type microbiota has been established.

13. The use according to any one of claims 1-12, wherein the composition is used as a food, medical food, dietary supplement or food additive.

14. The use according to any one of claims 1-13, wherein the composition is to be administered to a human or animal by a device selected from a naso-duodenal tube, gastroscope, colon/sigmoideoscope, and enema, or in freeze dried form in a suitable galenic preparation, e.g. gastric acid resistant capsule, nano-encapsulated or suppository.